Careers

Growing Stronger, Growing Better

Read more about the combination...

Our combination with Organon BioSciences is a transformational step on Schering-Plough’s continuing journey as we build a high-performance company for the long term.



Read more about the combination...

Basic Facts & Figures

World Headquarters
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530

Chairman and CEO
Fred Hassan

Number of employees
51,000

Net sales (2008)
$18.5 billion

Business Operations in
more than 140 countries

Largest-selling products
VYTORIN*, ZETIA*, REMICADE, NASONEX, TEMODAR

R&D investment (2008)
$3.5 billion

Areas of research
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $4.5 billion in 2008.

Total Compensation

Our Total Compensation Program is a key driver in Schering-Plough’s transformation to a high-performing company. It is designed to reward and motivate employees to deliver long-term results. Further, the program is aligned with our Vision and Mission, Leader Behaviors and performance expectations.

Compensation
Above all, Schering-Plough believes in paying for performance. That’s why our compensation program rewards those who make significant contributions toward achieving company objectives. This is the foundation of a high-performance culture.

Benefits
Benefit programs may vary by site and are generally designed to provide a level of medical, death and disability protection as well as access to retirement savings. Programs integrate with the company’s desire to deliver total compensation that is competitive in the marketplace.